Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual

BioRxiv : the Preprint Server for Biology
Emilie SeydouxLeonidas Stamatatos

Abstract

B cells specific for the SARS-CoV-2 S envelope glycoprotein spike were isolated from a COVID-19-infected subject using a stabilized spike-derived ectodomain (S2P) twenty-one days post-infection. Forty-four S2P-specific monoclonal antibodies were generated, three of which bound to the receptor binding domain (RBD). The antibodies were minimally mutated from germline and were derived from different B cell lineages. Only two antibodies displayed neutralizing activity against SARS-CoV-2 pseudo-virus. The most potent antibody bound the RBD in a manner that prevented binding to the ACE2 receptor, while the other bound outside the RBD. Our study indicates that the majority of antibodies against the viral envelope spike that were generated during the first weeks of COVID-19 infection are non-neutralizing and target epitopes outside the RBD. Antibodies that disrupt the SARS-CoV-2 spike-ACE2 interaction can potently neutralize the virus without undergoing extensive maturation. Such antibodies have potential preventive/therapeutic potential and can serve as templates for vaccine-design.

Citations

Jun 28, 2020·Journal of Virology·John P Moore, P J Klasse
Jul 22, 2020·The Journal of Experimental Medicine·Fabian SchmidtPaul D Bieniasz
Apr 22, 2021·MBio·Harini NatarajanMargaret E Ackerman
May 1, 2021·International Journal of Environmental Research and Public Health·Katharina MüllerJohannes P Borde
Jun 18, 2021·Frontiers in Molecular Biosciences·Arnaud John Kombe KombeTengchuan Jin

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
flow cytometry
biosensors
phage display

Related Concepts

Related Feeds

BioRxiv & MedRxiv Preprints

BioRxiv and MedRxiv are the preprint servers for biology and health sciences respectively, operated by Cold Spring Harbor Laboratory. Here are the latest preprint articles (which are not peer-reviewed) from BioRxiv and MedRxiv.